Pharma Stock to Watch! FIIs & DIIs Bet Big as This Drugmaker Launches a New Eye Treatment in the US!
FDA-Approved & Ready! This Pharma Giant Targets a USD 113 Million Market!
Glenmark Pharmaceuticals Inc., USA, has launched Latanoprost Ophthalmic Solution, 0.005% (0.05 mg/mL), expanding its ophthalmic product portfolio. The drug is a bioequivalent and therapeutically equivalent version of Xalatan® Ophthalmic Solution, 0.005%, manufactured by Upjohn US 2 LLC.
Market Potential and Growth Strategy
According to IQVIA sales data, the Xalatan® Ophthalmic Solution market achieved annual sales of approximately USD 113.5 million for the 12-month period ending December 2024. Glenmark aims to capture a share of this market through its latest launch, reinforcing its commitment to providing cost-effective, high-quality treatments.
Expanding Presence in Ophthalmic Segment
With this launch, Glenmark now has four ophthalmic products in its portfolio, strengthening its presence in this niche segment. Marc Kikuchi, President & Business Head, North America, stated that this addition highlights the company’s focus on expanding its offerings to meet market demand and provide affordable healthcare solutions.
Strong Market Position and Financial Performance
Glenmark is a global pharmaceutical company with operations in over 80 countries. The company has been reducing its debt and improving its financial efficiency. In the latest quarter, institutional investors have increased their holdings, with FIIs raising their stake from 20.98 per cent in June 2024 to 23.51 per cent in December 2024, while DIIs increased their stake from 13.21 per cent to 13.84 per cent in the same period.
Stock Valuation and Investor Confidence
Glenmark has a market capitalization of Rs 37,956 crore and a debt-to-equity ratio of 0.20, indicating a strong financial position. The company’s recent steps to streamline operations and expand its product portfolio have contributed to growing investor confidence, making it a stock to watch in the pharmaceutical sector.
Disclaimer: The article is for informational purposes only and not investment advice.